Marco Carlo Merlano

Dr. Marco Carlo Merlano

Candiolo Cancer Institute, FPO IRCCS, Turin, Italy
+2
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
ASAntonio Schindler
Antonio Schindler
NDNerina Denaro
Nerina Denaro
ERElvio G. Russi
Elvio G. Russi
NPNicole Pizzorni
Nicole Pizzorni
PBPaolo Bossi
Paolo Bossi
BMBarbara Murphy
Barbara Murphy

10 May 2014 in Oncology
Verified
Journal Article
Closed access
NDNerina Denaro
Nerina Denaro
ERElvio Grazioso Russi
Elvio Grazioso Russi
VAVincenzo Adamo
Vincenzo Adamo
Marco Carlo MerlanoMarco Carlo Merlano
Marco Carlo Merlano
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer death worldwide. Its treatment is complex and evolving. In general, early-stage disease may be managed with single-modality treatment while an advanced stage (about 60% of clinical presentation) needs a multidisciplinary approach. In this setting concurrent chemoradiation has been associated with improvement in locoregional control and organ preservation, but at the cost of significant acute and chronic toxicity. Molecular target therapies specially directed to epidermal growth factor receptor (EGFR) might improve the outcomes and reduce toxicities. In recurrent-metastatic (R/M) HNSCC, cetuximab, a monoclonal antibody against EGFR, plus platinum-based chemotherapy (CT) allow an overall survival (OS) of about 10 months. However, the prognosis for R/M-HNSCC remains dismal and additional efforts are needed. At the 2013 American Society of Clinical Oncology (ASCO) Meeting, data on induction CT, anti-EGFR inhibitors, innovative molecular targets and predictor factors were reported. Further results on target therapies were presented at the European Cancer Congress (ECC) 2013, where a large study also showed that hyperfractionated radiotherapy (RT) improve OS rates compared with standard RT. The aim of this review is to discuss current standards and emerging therapies by considering recent new updates.

1 October 2015 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
ERElvio G. Russi
Elvio G. Russi
FMFrancesco Moretto
Francesco Moretto
MRMonica Rampino
Monica Rampino
MBMarco Benasso
Marco Benasso
ABAlmalina Bacigalupo
Almalina Bacigalupo
HLHans Langendijk
Hans Langendijk

28 July 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Marco Carlo MerlanoMarco Carlo Merlano
Marco Carlo Merlano
NDNerina Denaro
Nerina Denaro
DGDanilo Galizia
Danilo Galizia
Fiorella RuattaFiorella Ruatta
Fiorella Ruatta
MOMarcella Occelli
Marcella Occelli
Ornella GarroneOrnella Garrone
Ornella Garrone
Chemotherapy is much more effective in immunocompetent mice than in immunodeficient ones, and it is now acknowledged that an efficient immune system is necessary to optimize chemotherapy activity and efficacy. Furthermore, chemotherapy itself may reinvigorate immune response in different ways: by targeting cancer cells through the induction of cell stress, the release of damage signals and the induction of immunogenic cell death, by targeting immune cells, inhibiting immune suppressive cells and/or activating immune effector cells; and by targeting the host physiology through changes in the balance of gut microbiome. All these effects acting on immune and non-immune components interfere with the tumor microenvironment, leading to the different activity and efficacy of treatments. This article describes the correlation between chemotherapy and the immune changes induced in the tumor microenvironment. Our ultimate aim is to pave the way for the identification of the best drugs or combinations, the doses, the schedules and the right sequences to use when chemotherapy is combined with immunotherapy.

1 October 2012 in Oral Oncology
Verified
Journal Article
Closed access
Marco Carlo MerlanoMarco Carlo Merlano
Marco Carlo Merlano
MMMartino Monteverde
Martino Monteverde
ICIda Colantonio
Ida Colantonio
NDNerina Denaro
Nerina Denaro
Cristiana Lo NigroCristiana Lo Nigro
Cristiana Lo Nigro
ERElvio Russi
Elvio Russi

1 January 2017 in ESMO Open
Verified
Journal Article
Open access
PDF file
Marco Carlo MerlanoMarco Carlo Merlano
Marco Carlo Merlano
CGCristina Granetto
Cristina Granetto
EFElena Fea
Elena Fea
VRVincenzo Ricci
Vincenzo Ricci
OGOrnella Garrone
Ornella Garrone
The large bowel shows biomolecular, anatomical and bacterial changes that proceed from the proximal to the distal tract. These changes account for the different behaviour of colon cancers arising from the diverse sides of the colon–rectum as well as for the sensitivity to the therapy, including immunotherapy. The gut microbiota plays an important role in the modulation of the immune response and differs between the right colon cancer and the left colorectal cancer. The qualitative and quantitative difference of the commensal bacteria between the right side and the left side induces epigenetic changes in the intestinal epithelial cells as well as in the resident immune population. The second player in the pathological homeostasis of colorectal cancer is the differences of the genetic features of cancer cells and the different effects that microsatellite instability, chromosomal instability and the CpG island methylator phenotype induce on the immunological organisation of the tumour microenvironment. The third player is the immunological composition of the tumour microenvironment, which changes under the influence of both genetic structures and gut microbiota. All these three players influence each other. This review describes these three aspects, highlights their interactions and discusses data from reported clinical trials. Click here to listen to the Podcast